# BCRX — BioCryst Pharmaceuticals · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** BCRX  
**Sources:** 18  
**Published:** 2026-10-28  
**Canonical:** https://app.k3vl4r.com/research/deep-research-bcrx-biocryst-pharmaceuticals-catalysts-narrative-risks-9804

---

## BioCryst Pharmaceuticals (BCRX) — Analysis as of 2026-10-28

**Context:** BioCryst is a Durham, North Carolina–based biotech building a dual-product hereditary angioedema (HAE) franchise around its oral drug Orladeyo (berotralstat) and the investigable injectable navenibart. As of late October 2026, the stock trades near $8, has a market cap of ~$2.1B, a 52-week range of $6.23–$11.22, a beta of 0.55, and no trailing P/E (TTM EPS of -$1.40) [[10]](https://finance.yahoo.com/quote/BCRX/). Below is a point-in-time review; it is not investment advice.

## Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-bcrx-biocryst-pharmaceuticals-catalysts-narrative-risks-9804 (free to sign up)._
